PacBio (PACB) announced that EpiCypher has joined the PacBio Compatible program. The partnership brings EpiCypher’s CUTANA Hia5 enzyme to market for use with Fiber-seq assays on PacBio HiFi sequencing systems, giving researchers a new way to see chromatin biology at single-molecule resolution. “EpiCypher is thrilled to partner with PacBio to bring our CUTANA Hia5 enzyme for Fiber-seq to a broader research community,” said Martis Cowles, PhD, Chief Business Officer at EpiCypher. “Together, we are enabling researchers to generate single-molecule insights that are essential to fully decoding gene regulation and accelerating breakthroughs across biology, agriculture, and medicine.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Cathie Wood Pours Over $46M into Biotech Stocks, 8/19/2025
- Pacific Biosciences’ Earnings Call Highlights Growth and Challenges
- PacBio price target raised to $1.50 from $1.25 at Piper Sandler
- Pacific Biosciences: Strong Q2 Performance and Strategic Initiatives Drive Buy Rating
- PacBio price target raised to $1.70 from $1.50 at Bernstein